PIA
PETX

Piedmont Investment Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Piedmont Investment Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-775
Closed -$3K – 2818
2018
Q2 		$3K Buy
+775
New +$3.91K ﹤0.01% 2505

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Piedmont Investment Advisors's PETX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 775 shares — an estimated $3K sold.

Piedmont Investment Advisors first reported a position in PETX in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 775 Aratana Therapeutics, Inc. shares in Q3 2018, an estimated $3K.
  • Piedmont Investment Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Aratana Therapeutics, Inc. position peaked at $3K in Q2 2018.
  • 100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.